Dupixent
- Product NDC
- 0024-5919
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Dupilumab
- Dosage form
- INJECTION, SOLUTION
- Route
- SUBCUTANEOUS
- Labeler
- Sanofi-Aventis U.S. LLC
- Application
- BLA761055
- Marketing category
- BLA
- Substance
- DUPILUMAB
- Current FDA listing
- Yes
Packages
| Package NDC | Description | Marketing start | Marketing end | Sample | Status |
|---|
| 0024-5919-02 | 2 SYRINGE, GLASS in 1 CARTON (0024-5919-02) / 1.14 mL in 1 SYRINGE, GLASS (0024-5919-00) | 2021-06-14 | | No | Historical |
| 0024-5919-20 | 2 SYRINGE, GLASS in 1 CARTON (0024-5919-20) / 1.14 mL in 1 SYRINGE, GLASS (0024-5919-01) | 2021-06-14 | | No | Historical |
Related DailyMed Labels
| Title | Manufacturer | Effective date | Type | Version |
|---|
| Dupixent | Sanofi-Aventis U.S. LLC | Regeneron Pharmaceuticals, Inc. | Sanofi Winthrop Industrie | Sanofi-Aventis Deutschland GmbH | Genzyme Ireland Limited | Regeneron Ireland Designated Activity Company | 2026-04-22 | HUMAN PRESCRIPTION DRUG LABEL | 56 |
| Dupixent | sanofi-aventis U.S. LLC | Regeneron Pharmaceuticals, Inc. | Sanofi-Winthrop Industrie | Sanofi-Aventis Deutschland GmbH | Regeneron Ireland Designated Activity Company | Genzyme Ireland Limited | 2025-06-18 | HUMAN PRESCRIPTION DRUG LABEL | 48 |